Oncology – Gastrointestinal
RCT: Maintenance Taxanes vs. surveillance in women with advanced ovarian/tubal/peritoneal cancer.
29 Jun, 2022 | 10:57h | UTCPhase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Consensus Statement: First-line PARP inhibitor maintenance for advanced, high-grade serous and endometrioid tubal, ovarian, and primary peritoneal cancers.
27 Jun, 2022 | 11:34h | UTC
RCT: Efficacy of Ipilimumab vs. FOLFOX in combination with Nivolumab and Trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma.
27 Jun, 2022 | 11:11h | UTCEfficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary: AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma – JAMA Oncology (free for a limited period)
Systematic Review: Locally recurrent rectal cancer according to a standardized MRI classification system.
27 Jun, 2022 | 11:07h | UTC
M-A: Relationship between serum lipid level and colorectal cancer.
27 Jun, 2022 | 11:01h | UTC
Dysplastic recurrence after successful treatment for early Barrett’s neoplasia: development and validation of a prediction model.
24 Jun, 2022 | 11:07h | UTC
Consensus report on anatomy, pathophysiology and clinical significance of the gastro-esophageal junction.
23 Jun, 2022 | 10:26h | UTC
Phase II RCT: FLOT vs. FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2–positive resectable esophagogastric adenocarcinoma.
23 Jun, 2022 | 09:58h | UTCFLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half.
21 Jun, 2022 | 11:11h | UTCOriginal Study: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/NEJM/status/1537185690961686528
Clinical and immunologic analyses of a phase II trial: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer.
21 Jun, 2022 | 10:26h | UTCNews Release: Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds – University of Pennsylvania
Commentary on Twitter
At #ASCO22 Symposium on targeted therapy in GI cancer?
Check out the results & biomarker analysis of the phase 2 PRINCE trial on a CD40 agonist, nivolumab and chemotherapy in #PancreaticCancer, led by speaker @laceykitch @parkerici
Published today 👉 https://t.co/8aUXuvDHIC
— Nature Medicine (@NatureMedicine) June 3, 2022
Radiomic assessment of esophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT.
20 Jun, 2022 | 00:53h | UTC
Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer in China: a national database study of 5055 patients.
15 Jun, 2022 | 10:49h | UTC
ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility.
14 Jun, 2022 | 10:59h | UTCCommentary: New guidelines for pancreatic cancer screening – Beth Israel Deaconess Medical Center
Commentary on Twitter
Sawhney et al share "ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations." https://t.co/P6OtmhXr2D pic.twitter.com/vDHWfKCAiN
— GIE (@GIE_Journal) May 26, 2022
Causes of liver cancer are changing around the world: some up, some down.
13 Jun, 2022 | 07:54h | UTCNews Release: Causes of Liver Cancer are Changing Around the World: Some Up, Some Down – UC San Diego Health
Original Study: Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer – Cell Metabolism (link to abstract – $ for full-text)
RCT: Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma.
9 Jun, 2022 | 10:24h | UTCTremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma – NEJM Evidence
Commentary on Twitter
Durvalumab plus a single dose of tremelimumab increased overall survival by just over 2.5 months in patients with unresectable hepatocellular carcinoma who had not received previous systemic therapy. Read more about the HIMALAYA trial by @GABOUALFA et al.: https://t.co/8d2qp54OLt pic.twitter.com/AA1RlSEP2a
— NEJM Evidence (@NEJMEvidence) June 6, 2022
Phase 2 RCT: Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer.
9 Jun, 2022 | 10:19h | UTCUpfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In phase II AtezoTRIBE study of the addition of atezolizumab to first-line FOLFOXIRI + bevacizumab improved PFS in pts with pMMR/MSS mCRC (median 13.1 vs 11.5 months; adjusted HR 0.70, 80% CI 0.57–0.87; P = 0.018): https://t.co/0dkRxjvjsx #ImmunoOnc #CRCSM
— NatureRevClinOncol (@NatRevClinOncol) May 31, 2022
Systematic Review: Guaiac‐based fecal occult blood tests versus fecal immunochemical tests for colorectal cancer screening in average‐risk individuals.
8 Jun, 2022 | 10:59h | UTC
Commentary on Twitter
💩 Which faecal blood test is more accurate in detecting #bowelcancer and large polyps in population screening? https://t.co/U2mLfk7ARo This systematic review looks at the evidence from 63 studies including almost 4 million individuals. @CochranePH @CCGlobalAgeing @CochraneCRC pic.twitter.com/xQeeADgHql
— The Cochrane Library (@CochraneLibrary) June 7, 2022
#ASCO22 – RCT: Upfront modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan plus Panitumumab vs. Fluorouracil, Leucovorin, and Oxaliplatin plus Panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer.
7 Jun, 2022 | 10:49h | UTC
#ASCO22 – RCT: Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.
6 Jun, 2022 | 11:53h | UTCCirculating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: ctDNA Effectively Detects When Adjuvant Chemo Is Avoidable in Stage II Colon Cancers – Cancer Network
Commentary on Twitter
DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9 pic.twitter.com/gvHMnGWbyE
— NEJM (@NEJM) June 4, 2022
#ADA2022 – Retrospective Cohort Study: Association of bariatric surgery with cancer risk and mortality in adults with obesity.
6 Jun, 2022 | 11:54h | UTCAssociation of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity – JAMA (free for a limited period)
Editorial: Bariatric Surgery and Cancer Risk – JAMA (free for a limited period)
News Release: Weight loss with bariatric surgery cuts the risk of developing cancer and death from cancer – Cleveland Clinic
Commentaries on Twitter
In this study, among adults with #obesity, #bariatricsurgery compared with no surgery was associated with a significantly lower incidence of obesity-associated #cancer and cancer-related mortality. https://t.co/x2gz3RUdra
— JAMA (@JAMA_current) June 3, 2022
Retrospective cohort presented at the @AmDiabetesAssn: incidence rate of 3.0 events vs 4.6 events per 1,000 person-years, resp, & a 32% reduced risk for developing obesity-related cancer following weight loss via surgery. @ClevelandClinic
https://t.co/6jLDmhgJbR @JAMA_current
— Karl Nadolsky (@DrKarlNadolsky) June 4, 2022
#ASCO22 – Phase 2 single-arm study: PD-1 Blockade in mismatch repair–deficient, locally advanced rectal cancer.
6 Jun, 2022 | 11:12h | UTCPD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Consensus Statement: Current role of immunotherapy in gastric, esophageal and gastro-esophageal junction cancers.
3 Jun, 2022 | 11:24h | UTC
Review: Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis.
3 Jun, 2022 | 10:51h | UTC
M-A: Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer.
3 Jun, 2022 | 10:46h | UTC
RCT: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
2 Jun, 2022 | 10:49h | UTCDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer – NEJM Evidence
Commentary on Twitter
Durvalumab, with gemcitabine plus cisplatin, increased median overall survival, 12.8 months versus 11.5 months, in patients with previously untreated unresectable, recurrent or metastatic biliary tract cancer. https://t.co/SaeUxfGfWd#OncTwitter #MedTwitter #Cholangiocarcinoma pic.twitter.com/NZeVljWnyu
— NEJM Evidence (@NEJMEvidence) June 1, 2022